Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.57 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.57 |
| ▸ | KDR | P35968 | 3/20 | 0.57 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.57 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 7/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | LIPC | P11150 | 1/20 | 0.43 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521611 | 0.88 | KDR (0.52) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL2387029 | 0.88 | KDR (0.52) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL18770716 | 0.88 | KDR (0.52) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL4036494 | 0.87 | TNK2 (0.53) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL29521878 | 0.87 | TNK2 (0.53) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL2386991 | 0.86 | KDR (0.51) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL18770648 | 0.83 | DDB1 (0.51) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL17310200 | 0.83 | MET (0.53) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL29521673 | 0.83 | KDR (0.48) | FGFR1FGFR2FGFR3KDRFGFR4 | |
| SCHEMBL29521692 | 0.81 | TNK2 (0.48) | FGFR1FGFR2FGFR3KDRFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | FGFR1 424/4885FGFR2 1125/4885FGFR3 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.